BR112014033066A2 - método para tratamento de um paciente diagnosticado com doença de alzheimer, forma humanizada, quimérica ou revestida de um anticorpo, e, anticorpo. - Google Patents

método para tratamento de um paciente diagnosticado com doença de alzheimer, forma humanizada, quimérica ou revestida de um anticorpo, e, anticorpo.

Info

Publication number
BR112014033066A2
BR112014033066A2 BR112014033066A BR112014033066A BR112014033066A2 BR 112014033066 A2 BR112014033066 A2 BR 112014033066A2 BR 112014033066 A BR112014033066 A BR 112014033066A BR 112014033066 A BR112014033066 A BR 112014033066A BR 112014033066 A2 BR112014033066 A2 BR 112014033066A2
Authority
BR
Brazil
Prior art keywords
antibody
humanized
alzheimer
chimeric
disease
Prior art date
Application number
BR112014033066A
Other languages
English (en)
Portuguese (pt)
Inventor
Buttini Manuel
Chen Ming
Gardal Shyra
Original Assignee
Janssen Alzheimer Immunotherap
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Alzheimer Immunotherap, Wyeth Llc filed Critical Janssen Alzheimer Immunotherap
Publication of BR112014033066A2 publication Critical patent/BR112014033066A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
BR112014033066A 2012-07-03 2013-06-18 método para tratamento de um paciente diagnosticado com doença de alzheimer, forma humanizada, quimérica ou revestida de um anticorpo, e, anticorpo. BR112014033066A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261667891P 2012-07-03 2012-07-03
PCT/US2013/046399 WO2014007982A2 (en) 2012-07-03 2013-06-18 C-terminal and central epitope a-beta antibodies

Publications (1)

Publication Number Publication Date
BR112014033066A2 true BR112014033066A2 (pt) 2017-08-01

Family

ID=49882576

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014033066A BR112014033066A2 (pt) 2012-07-03 2013-06-18 método para tratamento de um paciente diagnosticado com doença de alzheimer, forma humanizada, quimérica ou revestida de um anticorpo, e, anticorpo.

Country Status (13)

Country Link
US (1) US20150353631A1 (cg-RX-API-DMAC7.html)
EP (1) EP2869846A4 (cg-RX-API-DMAC7.html)
JP (1) JP2015526409A (cg-RX-API-DMAC7.html)
KR (1) KR20150036163A (cg-RX-API-DMAC7.html)
CN (1) CN105579061A (cg-RX-API-DMAC7.html)
AU (1) AU2013287119A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014033066A2 (cg-RX-API-DMAC7.html)
CA (1) CA2877516A1 (cg-RX-API-DMAC7.html)
HK (1) HK1208810A1 (cg-RX-API-DMAC7.html)
IL (1) IL236549A0 (cg-RX-API-DMAC7.html)
MX (1) MX2014015744A (cg-RX-API-DMAC7.html)
RU (1) RU2014153675A (cg-RX-API-DMAC7.html)
WO (1) WO2014007982A2 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112552401B (zh) 2013-09-13 2023-08-25 广州百济神州生物制药有限公司 抗pd1抗体及其作为治疗剂与诊断剂的用途
CN106604742B (zh) 2014-07-03 2019-01-11 百济神州有限公司 抗pd-l1抗体及其作为治疗剂及诊断剂的用途
BR112017001385B1 (pt) 2014-07-22 2023-12-05 Cb Therapeutics, Inc. Anticorpo isolado ou fragmento do mesmo que liga a pd-1, uso deste, composição, polinucleotídeo isolado e vetor de expressão
KR102476226B1 (ko) 2014-08-05 2022-12-12 아폴로믹스 인코포레이티드 항-pd-l1 항체
JP2018534334A (ja) * 2015-11-20 2018-11-22 ナビディア・バイオファーマシューティカルズ，インコーポレーテッド ２−ヘテロアリール置換ベンゾフラン類のための製剤
KR20250057128A (ko) * 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
CN105542005B (zh) * 2016-02-03 2018-11-09 大连理工大学 一种抗人淀粉样β肽的纳米抗体及其应用
US10864203B2 (en) 2016-07-05 2020-12-15 Beigene, Ltd. Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
WO2018033135A1 (en) 2016-08-19 2018-02-22 Beigene, Ltd. Use of a combination comprising a btk inhibitor for treating cancers
US11555038B2 (en) 2017-01-25 2023-01-17 Beigene, Ltd. Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
EP3645569A4 (en) 2017-06-26 2021-03-24 BeiGene, Ltd. IMMUNOTHERAPY FOR LIVER CELL CARCINOMA
WO2019108795A1 (en) 2017-11-29 2019-06-06 Beigene Switzerland Gmbh Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors
KR20230039734A (ko) 2020-07-23 2023-03-21 오타이르 프로테나 리미티드 항-Aβ 항체
CN118382636A (zh) 2021-12-17 2024-07-23 豪夫迈·罗氏有限公司 一种用于检测淀粉样蛋白β42(Aβ42)的新抗体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9125798A (en) * 1997-08-28 1999-03-16 University Of Washington Specific saccharide compositions and methods for treating alzheimer's disease and other amyloidoses
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
DE1257584T1 (de) * 2000-02-24 2003-05-28 Lilly Co Eli Humanisierte antikörper, die amyloid beta peptid demarkieren
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
AR038568A1 (es) * 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
WO2005018424A2 (en) * 2003-08-18 2005-03-03 Research Foundation For Mental Hygiene, Inc. Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
CA2589017A1 (en) * 2004-12-15 2006-06-22 Neuralab Limited Amyloid beta antibodies for use in improving cognition
PA8661401A1 (es) * 2005-01-28 2006-09-08 Wyeth Corp Formulaciones del liquido polipeptido estabilizado
EP1959996A2 (en) * 2005-12-12 2008-08-27 AC Immune S.A. Monoclonal antibody
EP2527369A3 (en) * 2007-09-13 2012-12-19 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
US20130084245A1 (en) * 2010-02-25 2013-04-04 Wyeth Llc Pet monitoring of a-beta-directed immunotherapy
EP2560681A4 (en) * 2010-04-22 2013-09-25 Janssen Alzheimer Immunotherap USE OF TAU FOR MONITORING IMMUNOTHERAPY

Also Published As

Publication number Publication date
IL236549A0 (en) 2015-02-26
RU2014153675A (ru) 2016-08-27
CN105579061A (zh) 2016-05-11
KR20150036163A (ko) 2015-04-07
US20150353631A1 (en) 2015-12-10
CA2877516A1 (en) 2014-01-03
JP2015526409A (ja) 2015-09-10
EP2869846A4 (en) 2016-01-13
MX2014015744A (es) 2015-06-05
WO2014007982A3 (en) 2014-04-03
HK1208810A1 (en) 2016-03-18
AU2013287119A1 (en) 2015-01-22
EP2869846A2 (en) 2015-05-13
WO2014007982A2 (en) 2014-01-09

Similar Documents

Publication Publication Date Title
BR112014033066A2 (pt) método para tratamento de um paciente diagnosticado com doença de alzheimer, forma humanizada, quimérica ou revestida de um anticorpo, e, anticorpo.
IL235261B (en) Antibodies against claudin 18.2 useful in cancer diagnosis
IL275092A (en) Methods for treating Crohn's disease using an anti-IL-23 antibody
IL235607A0 (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
PL3725810T3 (pl) Terapia skojarzona obejmująca przeciwciała przeciwko Klaudynie 18.2 do leczenia nowotworu złośliwego
EP2882295A4 (en) ANTIMICROBIAL SOLID SURFACES AND TREATMENTS AND METHOD FOR THE PRODUCTION THEREOF
PL2958945T3 (pl) Terapia skojarzona wykorzystująca przeciwciała przeciwko klaudynie 18.2 do leczenia nowotworu
PT3016681T (pt) Anticorpos humanizados ou quiméricos cd3
WO2014152006A3 (en) Anti-hepcidin antibodies and uses thereof
LT2958943T (lt) Vėžio gydymas, naudojant humanizuotą anti-egfrviii chimerinio antigeno receptorių
WO2015010100A3 (en) Humanized antibodies with ultralong complementarity determining regions
HUE049012T2 (hu) Antitestek S. aureus felszíni determinánsok ellen
BR112014002621A2 (pt) anticorpo, composição farmacêutica, combinação farmacêutica, dna e método de tratamento
WO2012166626A8 (en) Reagents and methods for treating dental disease
BR112013031712A2 (pt) composto, composição farmacêutica, métodos para preparar um composto e para o tratamento de um distúrbio ou uma doença.
WO2015017146A3 (en) Antibodies with ultralong complementarity determining regions
IL258914A (en) Antibodies against kidney associated antigen 1 and antigen binding fragments thereof
BR112013031117A2 (pt) scilo-inositol para o tratamento de transtornos comportamentais e psiquiátricos.
BR112014025299A8 (pt) anticorpo de reação cruzada dirigido contra staphylococcus aureus, preparação farmacêutica e diagnóstica compreendendo o anticorpo, métodos de anticorpo de reação cruzada contra staphylococcus aureus
EP3006465A4 (en) Anti-vegf antibody, and pharmaceutical composition for preventing, diagnosing or treating cancer or angiogenesis-related diseases, containing same
WO2016057683A3 (en) Novel anti-nodal antibodies and methods of using same
FR3004967B1 (fr) Procede de preparation d'un catalyseur a base de molybdene utilisable en hydrotraitement ou en hydrocraquage
SG11201506358PA (en) Anti-cdh3 humanized antibody, drug conjugate thereof, and use thereof
LT2814843T (lt) ŽMOGAUS MONOKLONINIAI ANTIKŪNAI, NEUTRALIZUOJANTYS IL-1ß
BR112015003032A2 (pt) anticorpos anti-jagged e métodos de utilização'.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: WYETH LLC (US) ; JANSSEN SCIENCES IRELAND UC (IE)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2519 DE 16-04-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]